This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thompson, C. J. Articles by Ho, S.-m. Search for Related Content PubMed PubMed Citation Articles by Thompson, C. J. Articles by Ho, S.-m.

Gene Expression Profiling of Testosterone and Estradiol-17ß-Induced Prostatic Dysplasia in Noble Rats and Response to the Antiestrogen ICI 182,780

Department of Surgery-Division of Urology (C.J.T., N.N.C.T., J.M.J., I.L., S.-M.H.), Department of Cell Biology, and Department of Physiology, University of Massachusetts Medical School, Worcester, Massachusetts 01655; Department of Pathology (I.L.), School of Veterinary Medicine, Tufts University, Grafton, Massachusetts 01536; and Department of Pathology (I.L.), University of Massachusetts Medical School, Worcester, Massachusetts 01655

Address all correspondence and requests for reprints to: Dr. Shuk-Mei Ho, Room S4-746, Division of Urology, Department of Surgery, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, Massachusetts 01655. E-mail: . Shuk-mei.Ho{at}umassmed.edu

We previously demonstrated that 1) treatment of Noble rats for 16 wk with testosterone (T) and estradiol-17ß (E2) led to 100% incidence of dorsolateral prostate (DLP) dysplasia and hyperprolactinemia and 2) blockade of PRL release with bromocriptine cotreatment significantly lowered the incidence of DLP dysplasia. In the current study, we sought to determine whether E2 exerts direct effects, independent of PRL, in this model system. The pure antiestrogen ICI 182,780 (ICI), reported to have no effect on PRL release in female rats, was administered biweekly to T + E2-treated rats at 3 mg/kg body weight. ICI cotreatment completely prevented DLP dysplasia development but it also blocked hyperprolactinemia in the dual hormone-treated rats. Gene profiling with an 1185 gene rat cDNA array identified 100 genes displaying 3-fold changes in rat lateral prostates (LPs) following T + E2 treatment. Significantly more genes were up-regulated (77) than down-regulated (14), reflecting cellular/molecular changes associated with enhanced cell proliferation, DNA damage, heightened protein and RNA synthesis, increased energy metabolism, and activation of several proto-oncogenes and intracellular signaling pathways. Post hoc analyses, using quantitative real-time RT-PCR, corroborated differential expression of eight genes, exhibiting three different patterns of altered expression. Genes encoding the early growth response protein 1 and metalloendopeptidase meprin ß-subunit were similarly altered in T + E2- and T + E2 + ICI-treated animals when compared with untreated controls. In contrast, transcripts of fos-related antigen-2, growth arrest and DNA damage-inducible protein-45, and signal transducer and activator of transcription-3 were significantly increased in the LPs of T + E2-treated animals, but the increases were reversed by cotreatment with ICI. Differential expression of fos-related antigen-2 and growth arrest and DNA damage-inducible protein-45 were further confirmed at the protein level by immunohistochemistry. Lastly, levels of A-RAF, VIP-1 receptor, and calpastatin mRNA were distinctly lessen in rat LPs under T + E2 influence, but rebound with ICI cotreatment. In conclusion, our findings further implicated pituitary PRL in the induction of dysplasia in rat LP. Gene profiling provided clues that molecular events related to enhancement of cell proliferation, DNA damage, and activation of proto-oncogenes and transforming factors may be causally linked to the genesis of LP dysplasia in this rat model.

This article has been cited by other articles:

				E. Yatkin, J. Bernoulli, R. Lammintausta, and R. Santti Fispemifene [Z-2-{2-[4-(4-Chloro-1,2-diphenylbut-1-enyl)-phenoxy]ethoxy}-ethanol], a Novel Selective Estrogen Receptor Modulator, Attenuates Glandular Inflammation in an Animal Model of Chronic Nonbacterial Prostatitis J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 58 - 67. [Abstract] [Full Text] [PDF]

				N. N.C. Tam, I. Leav, and S.-M. Ho Sex Hormones Induce Direct Epithelial and Inflammation-Mediated Oxidative/Nitrosative Stress That Favors Prostatic Carcinogenesis in the Noble Rat Am. J. Pathol., October 1, 2007; 171(4): 1334 - 1341. [Abstract] [Full Text] [PDF]

				R. O'Lone, K. Knorr, I. Z. Jaffe, M. E. Schaffer, P. G. V. Martini, R. H. Karas, J. Bienkowska, M. E. Mendelsohn, and U. Hansen Estrogen Receptors {alpha} and {beta} Mediate Distinct Pathways of Vascular Gene Expression, Including Genes Involved in Mitochondrial Electron Transport and Generation of Reactive Oxygen Species Mol. Endocrinol., June 1, 2007; 21(6): 1281 - 1296. [Abstract] [Full Text] [PDF]

				U. S. Shah, J. Arlotti, R. Dhir, S. Lu, G. Pirozzi, K. Prakash, and R. H. Getzenberg Androgen Regulation of JM-27 Is Associated With the Diseased Prostate J Androl, July 1, 2004; 25(4): 618 - 624. [Abstract] [Full Text] [PDF]

				N. N. C. Tam, Y. Gao, Y.-K. Leung, and S.-M. Ho Androgenic Regulation of Oxidative Stress in the Rat Prostate: Involvement of NAD(P)H Oxidases and Antioxidant Defense Machinery during Prostatic Involution and Regrowth Am. J. Pathol., December 1, 2003; 163(6): 2513 - 2522. [Abstract] [Full Text]